Shakeel Usmani, MD
Internal Medicine · Auburn, NYNPI 1275715153
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $824 of the $947 with a category attached, or 87.0%. 10 manufacturers reported payments, led by AbbVie at 50.4% of the total. Reporting peaked in 2019 at $307 and has fallen 65.7% since, to $105 in 2024.
Across 53 payments — averaging $17.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$477
- Vifor Pharma, Inc.$124
- Portola Pharmaceuticals, LLC$83
- AstraZeneca$69
- Pfizer$59
- Novartis$37
- plus $98 from 4 others
What the payments were for
- Food & beverage$82487%
- Education$12413%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 29 | $477 |
| Vifor Pharma, Inc. | 3 | $124 |
| Portola Pharmaceuticals, LLC | 5 | $83 |
| AstraZeneca | 4 | $69 |
| Pfizer | 4 | $59 |
| Novartis | 2 | $37 |
| Bioxcel Therapeutics, Inc. | 2 | $33 |
| Melinta Therapeutics, LLC | 2 | $31 |
| Mallinckrodt Hospital Products Inc. | 1 | $17 |
| Johnson & Johnson | 1 | $16 |
How this compares
$947 in reported general payments places this provider in the 70th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cephalexin | 86 | $464 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 46 | $416 |
| Methylprednisolone | 45 | $335 |
| Doxycycline Monohydrate | 11 | $233 |
| Cyclobenzaprine Hcl | 39 | $163 |
| Metronidazole | 22 | $158 |
| Ciprofloxacin Hcl | 44 | $154 |
| Ondansetron OdtOndansetron | 13 | $108 |
| Pantoprazole Sodium | 17 | $106 |
| Meclizine Hcl | 12 | $38 |
| Azithromycin | 14 | $31 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Auburn
- David DoveEast Hampton$12.3M
- Bruce BergerBrooklyn$3.4M
- Nicholas RobinsonBuffalo$2.9M
- Stephen SaletanNew York$2.6M
- Ziad AliNew York$2M
- Scott BeegleAlbany$1.9M
- Anthony MartinezBuffalo$1.6M
- Javier MoralesGreenvale$1.3M
- Ricky HsuNew York$1M
- James UnderbergNew York$953K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.